MAPT and Alzheimer disease: Together with structural MRI, these biomarkers form the framework of the A/T/N system for antemortem AD diagnosis defined by the National Institute on Aging and Alzheimer’s Association (NIA-AA), where “A” refers to amyloid, “T” refers to tau, and “N” refers to neurodegeneration [2].